Godefroy Jeremy, Godefroy Raphael, Vedder Koral, Altura Yair, Chicheportiche Alexandre, Ben-Haim Simona, Goldstein Gal
Department of Medical Biophysics and Nuclear Medicine, Hadassah Medical Center, Jerusalem, Israel.
Department of Economics, Universite de Montreal, Montreal, QC, Canada.
EJNMMI Res. 2024 May 29;14(1):52. doi: 10.1186/s13550-024-01110-9.
F-18-flurodeoxyglucose (FDG) PET/CT is routinely used for staging, evaluation of response to treatment and follow-up of most pediatric malignancies. Cervical lymph nodes can be involved in some pediatric malignancies, but increased uptake in non-malignant cervical lymph nodes is not exceptional in this population. The aim of the present study is to identify predictors of the maximum uptake in non-malignant cervical lymph nodes in the pediatric population.
191 FDG PET/CT studies of pediatric patients without malignant involvement of cervical lymph nodes were retrospectively reviewed. The maximal Standard Uptake Value in the hottest cervical lymph node (SUVmax), as well as demographic, technical and imaging variables were recorded. The predictive effect of those variables on SUVmax was estimated using linear regression models.
Increased FDG activity in cervical nodes was observed in 136/191 studies (71%). The mean SUVmax was 2.2 ± 1.3. Ipsilateral palatine tonsil SUVmax, mean liver uptake, and treatment status were all statistically significant predictors of SUVmax. However, in multivariate regression analysis, only ipsilateral palatine tonsil SUVmax was found to be significant. In addition, SUVmax was greater than the mean liver uptake in 50% of all studies. This proportion was higher in younger children, reaching 77% of studies of children younger than six years.
SUVmax in ipsilateral palatine tonsil is a strong predictor of the maximal uptake value of non-malignant cervical lymph nodes in children. The intensity of uptake in non-malignant cervical lymph nodes is frequently higher than liver uptake in children, and this tendency increases for younger patients.
In the internal hospital registry under TRN 0209-22-HMO on date 23.04.2022.
F-18-氟脱氧葡萄糖(FDG)PET/CT常用于大多数小儿恶性肿瘤的分期、治疗反应评估及随访。某些小儿恶性肿瘤可累及颈部淋巴结,但在该人群中,非恶性颈部淋巴结摄取增加并不罕见。本研究旨在确定小儿人群中非恶性颈部淋巴结最大摄取量的预测因素。
回顾性分析191例小儿患者的FDG PET/CT检查,这些患者的颈部淋巴结无恶性病变。记录最热点颈部淋巴结的最大标准摄取值(SUVmax)以及人口统计学、技术和影像变量。使用线性回归模型评估这些变量对SUVmax的预测作用。
191项研究中有136项(71%)观察到颈部淋巴结FDG活性增加。平均SUVmax为2.2±1.3。同侧腭扁桃体SUVmax、肝脏平均摄取量及治疗状态均为SUVmax的统计学显著预测因素。然而,在多变量回归分析中,仅同侧腭扁桃体SUVmax具有显著性。此外,在所有研究中,50%的SUVmax大于肝脏平均摄取量。该比例在年幼儿童中更高,在6岁以下儿童的研究中达到77%。
同侧腭扁桃体的SUVmax是儿童非恶性颈部淋巴结最大摄取值的有力预测因素。儿童非恶性颈部淋巴结的摄取强度通常高于肝脏摄取,且这种趋势在较年轻患者中更明显。
于2022年4月23日在医院内部注册登记,注册号为TRN 0209-22-HMO。